Justices Must Resolve Off-Label Drug Warning Predicament
Law360 (May 10, 2021, 5:41 PM EDT) -- The U.S. Supreme Court will soon decide whether to hear a case, Janssen Pharmaceuticals Inc. v. AY, involving the off-label use of drugs approved by the U.S. Food and Drug Administration.
This case has wide-ranging implications for the practice of medicine, drug-pricing and, more importantly, patient access to medically necessary and often lifesaving therapies.
In the U.S., physicians may lawfully administer and prescribe FDA-approved drugs for off-label uses — i.e., uses that are not included in the drug's FDA-approved label. The practice, which accounts for roughly 20% of all prescriptions, is both common and critical to the public health.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!